Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guérin vaccine in High-Risk Bladder Cancer

Ryan J. Brown; Mairah T. Khan; Andrew J. Houston; Hongshen Niu; Joseph R. Podojil; Bonnie Choy; Weiguo Cui; Joshua James Meeks

doi:10.1172/JCI200442

Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guérin vaccine in High-Risk Bladder Cancer

Ryan J. Brown,¹ Mairah T. Khan,² Andrew J. Houston,² Hongshen Niu,¹ Joseph R. Podojil,¹ Bonnie Choy,³ Weiguo Cui,¹ and Joshua James Meeks²

Published May 4, 2026 - More info

View PDF

Abstract

BACKGROUND. Primary therapy for high-risk bladder cancer (BCa) is repeated instillations of the tuberculosis vaccine Bacillus Calmette-Guerin (BCG). Although BCG reduces the risk of recurrence by more than half, the mechanisms underlying its immune-activating effects remain unknown. Our objective was to investigate how the immune response differs between BCG responders and non-responders and to compare systemic and local immune responses. METHODS. We performed single-cell RNA sequencing (scRNA-seq) of isolated immune cells adjacent to high-risk bladders in BCG responders and non-responders before and after BCG. We also compared concurrent scRNA-seq profiles of circulating immune cell populations with those of bladder immune cells. RESULTS. We identify an increase in Th17-like Th1 cells in BCG responders, characterized by greater expression of pro-inflammatory cytokines. Alternatively, non-responders show increased CD8+ T-cell exhaustion and T regulatory cells. We identify that the primary mechanism driving divergent T-cell activity is altered polarization and immunosuppressive signaling with myeloid cells. Using a machine-learning-based approach, we identify that Th17-like Th1 cytokines, such as IL-17, IL-21, and IL-26, are predictive of response, which is subsequently validated in a separate BCG-treated BCa cohort. CONCLUSION. Together, these findings suggest that dynamic regulation of myeloid-T cell interactions can be critical for outcomes of BCG treated bladder cancer.

Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guérin vaccine in High-Risk Bladder Cancer

Ryan J. Brown,¹ Mairah T. Khan,² Andrew J. Houston,² Hongshen Niu,¹ Joseph R. Podojil,¹ Bonnie Choy,³ Weiguo Cui,¹ and Joshua James Meeks²

Article tools

Metrics

Go to

Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guérin vaccine in High-Risk Bladder Cancer

Ryan J. Brown,1 Mairah T. Khan,2 Andrew J. Houston,2 Hongshen Niu,1 Joseph R. Podojil,1 Bonnie Choy,3 Weiguo Cui,1 and Joshua James Meeks2

Article tools

Metrics

Go to

Sign up for email alerts

Ryan J. Brown,¹ Mairah T. Khan,² Andrew J. Houston,² Hongshen Niu,¹ Joseph R. Podojil,¹ Bonnie Choy,³ Weiguo Cui,¹ and Joshua James Meeks²